For patients with resected stage IIIA (metastasis > 1 mm), IIIB and IIIC melanoma (AJCCv7) harbouring the BRAF V600E or V600K mutations, the COMBI-AD trial demonstrated significantly improved RFS with combination BRAF/MEK inhibitors dabrafenib and trametinib compared with placebo [5, 12]. The gene discussed is BRAF; the disease is melanoma.